Robert Langreth

New York

Science and Health Reporter-at-Large at Bloomberg News

Science and health reporter at large, Bloomberg News

Featured in: Favicon

bloomberg.com Favicon

uol.com.br (+1) Favicon

forbes.com Favicon

msn.com

elpais.com Favicon

indiatimes.com (+1) Favicon

huffpost.com Favicon

independent.co.uk Favicon

washingtonpost.com Favicon

time.com + 92 more

Articles

Cancer Treatment Studies, Walking and Early Immunotherapy, at ASCO

3 days ago | bloomberg.com | Robert Langreth |Damian Garde

Hi, it’s Bob from Chicago, where I spent my weekend talking to oncologists. And it’s Damian in New York, where I monitored the cancer conference from afar. Here’s what we learned. But first ... Every year around this time, some 40,000 oncologists and oncology drug developers from around the world descend on the massive convention center here in Chicago for the American Society of Clinical Oncology annual meeting.
Breast Cancer Growth Slowed by 14 Months in New AstraZeneca Drug Study

4 days ago | bloomberg.com | Robert Langreth

A Breast Cancer Awareness ribbon in New York City. (Bloomberg) -- AstraZeneca Plc and Daiichi Sankyo Co.’s Enhertu delayed the advance of a common type of breast cancer by more than a year in a large study, a result that may lead to expanded use of the medicine. The treatment, already approved for several types of breast cancer, garnered sales of about $3.8 billion last year. It is routinely used as a second choice in roughly 20% of patients whose tumors have high levels of a protein called HER2.
Immunotherapy Drugs Show Major Progress in Early-Stage Cancer

5 days ago | news.bloomberglaw.com | Robert Langreth |Damian Garde

Drugs that boost the body’s immune system to fight disease are showing promise in treating a variety of cancers in earlier stages, a development primed to expand their use and transform care for stubborn diseases like gastric and colon cancer. Immunotherapy treatments such as Opdivo from Bristol Myers Squibb Co., Imfinzi from AstraZeneca PLC, and Roche Holding AG’s Tecentriq have become bestsellers by increasing survival times in a number of advanced cancers.
Immunotherapy Drugs Show Major Progress in Early-Stage Cancer

5 days ago | bloomberg.com | Robert Langreth |Damian Garde

Saline Drip Hanging On Metal Hook Against Wall In Hospital rf IV hospital(Bloomberg) -- Drugs that boost the body’s immune system to fight disease are showing promise in treating a variety of cancers in earlier stages, a development primed to expand their use and transform care for stubborn diseases like gastric and colon cancer.
Expensive Cancer Drugs That Don't Always Work Got FDA Approval

1 week ago | bloomberg.com | Robert Langreth

Hi, its Bob in soggy New Jersey. I’m about to head to the big annual cancer conference in Chicago. How many of those new drugs save lives? More on that in a moment, but first ... I’ve been reporting on the FDA’s expedited drug approval process for a couple of years now. Critics say it’s helped drug companies make billions on drugs that turned out to be ineffective. And the cost of cancer drugs came up again and again.
Cancer Drugs Cost More Than Ever. They Often Don’t Extend Lives

1 week ago | news.bloomberglaw.com | Robert Langreth |Tanaz Meghjani |Rachael Dottle

For the full experience visit: Cancer Drugs Cost More Than Ever. They Often Don’t Extend LivesThe moment she heard that her mother, then 67, had advanced breast cancer, Stacie Dusetzina began hunting for potential treatments. A cancer policy researcher at Vanderbilt University, Dusetzina knew the go-to drug in many cases was Pfizer Inc.’s Ibrance. She learned it might cost her mother, who lived on a fixed income, around $10,000 out of pocket annually.
Cancer Drugs Cost More Than Ever. They Often Don’t Extend Lives

1 week ago | news.bloomberglaw.com | Robert Langreth |Tanaz Meghjani |Rachael Dottle

For the full experience visit: Cancer Drugs Cost More Than Ever. They Often Don’t Extend LivesThe moment she heard that her mother, then 67, had advanced breast cancer, Stacie Dusetzina began hunting for potential treatments. A cancer policy researcher at Vanderbilt University, Dusetzina knew the go-to drug in many cases was Pfizer Inc.’s Ibrance. She learned it might cost her mother, who lived on a fixed income, around $10,000 out of pocket annually.
Cancer Drugs Cost More Than Ever. They Often Don’t Extend Lives

1 week ago | bloomberg.com | Robert Langreth |Tanaz Meghjani |Rachael Dottle

Industries | The Big Take By Robert Langreth Tanaz Meghjani Rachael Dottle May 28, 2025 The moment she heard that her mother, then 67, had advanced breast cancer, Stacie Dusetzina began hunting for potential treatments. A cancer policy researcher at Vanderbilt University, Dusetzina knew the go-to drug in many cases was Pfizer Inc.’s Ibrance. She learned it might cost her mother, who lived on a fixed income, around $10,000 out of pocket annually.
FDA clears first blood test to diagnose Alzheimer’s disease

2 weeks ago | billingsgazette.com | Gerry Smith |Robert Langreth

U.S. regulators have approved the first blood test to help diagnose Alzheimer’s disease, potentially making it easier to find and treat patients with the mind-robbing disease that affects nearly 7 million Americans. The test made by Fujirebio Diagnostics Inc., a unit of Japan’s H.U. Group Holdings Inc., was cleared for people 55 years and older who exhibit signs and symptoms of the disease, the U.S. Food and Drug Administration said in a statement.
Alzheimer’s blood test cleared in the US in ‘game changer’

2 weeks ago | afr.com | Gerry Smith |Robert Langreth

Gerry Smith and Robert LangrethMay 17, 2025 – 10.09pm or Subscribe to save articleSubscribe to gift this articleGift 5 articles to anyone you choose each month when you subscribe. Subscribe nowAlready a subscriber? US regulators have approved the first blood test to help diagnose Alzheimer’s disease, potentially making it easier to find and treat patients with the mind-robbing disease that affects nearly 7 million Americans.